1. Home
  2. Analysis
  3. Gemfibrozil
  4. Medrol

Gemfibrozil and Medrol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gemfibrozil (gemfibrozil) and Medrol (methylprednisolone). Common drug interactions include alcohol use among females and abdominal pain among males.

The phase IV clinical study analyzes what interactions people have when they take Gemfibrozil and Medrol. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Gemfibrozil?

Gemfibrozil has active ingredients of gemfibrozil. It is often used in high blood cholesterol. eHealthMe is studying from 18,213 Gemfibrozil users. Check the latest studies of Gemfibrozil.

What is Medrol?

Medrol has active ingredients of methylprednisolone. It is often used in rheumatoid arthritis. eHealthMe is studying from 24,443 Medrol users. Check the latest studies of Medrol.

On Aug, 08, 2026

25 people who take Gemfibrozil and Medrol together, and have interactions are studied.

Gemfibrozil and Medrol drug interactions.

What are the common drug interactions of Gemfibrozil and Medrol, by gender? *:

female:

  1. Alcohol use
  2. Anxiety
  3. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  4. Blood magnesium decreased
  5. Blood potassium decreased
  6. Blood pressure increased
  7. Blood urine present
  8. Bone disorder
  9. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  10. Carpal tunnel syndrome (nerve compression at wrist results numbness weakness, pain , swelling)

male:

  1. Abdominal pain
  2. Pain
  3. Injury
  4. Musculoskeletal chest pain (pain in chest muscle or nerve or bones)
  5. Nasopharyngitis (inflammation of the nasopharynx)
  6. Nausea (feeling of having an urge to vomit)
  7. Oedema peripheral (superficial swelling)
  8. Oxygen saturation decreased
  9. Pain in extremity
  10. Procedural site reaction

What are the common drug interactions of Gemfibrozil and Medrol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Fall
  2. Femur fracture
  3. Haemoglobin decreased
  4. Mobility decreased (ability to move is reduced)
  5. Nervous system disorder (a general class of medical conditions affecting the nervous system)
  6. Pain in extremity
  7. Viith nerve paralysis
  8. Cellulitis (infection under the skin)
  9. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  10. Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)

30-39:

  1. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)

40-49:

n/a

50-59:

  1. Fistula (an abnormal connection or passageway between two)
  2. Wound dehiscence (a surgical incision reopens either internally or externally)

60+:

  1. Neutropenia (an abnormally low number of neutrophils)
  2. Abdominal pain upper
  3. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  4. Hyperkalaemia (damage to or disease of the kidney)
  5. Hyperuricaemia (level of uric acid in the blood that is abnormally high)
  6. Hypocalcaemia (levels of calcium in blood serum are abnormally low)
  7. Leukopenia (less number of white blood cells in blood)
  8. Pain
  9. Pruritus (severe itching of the skin)
  10. Rash pustular (redness with pustules)

What are the existing conditions these people have? *

  1. Pain: 8 people, 32.00%
  2. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 4 people, 16.00%
  3. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 12.00%
  4. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 3 people, 12.00%
  5. Breast Cancer: 3 people, 12.00%
  6. Stress And Anxiety: 2 people, 8.00%
  7. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 2 people, 8.00%
  8. Neutrophil Count Abnormal (abnormal number of neutrophil a type of blood cell): 2 people, 8.00%
  9. Hypertriglyceridaemia (excess of triglycerides in the blood): 2 people, 8.00%
  10. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Gemfibrozil and Medrol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Gemfibrozil and Medrol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gemfibrozil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Medrol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gemfibrozil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Medrol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gemfibrozil and methylprednisolone (the active ingredients of Gemfibrozil and Medrol, respectively), and Gemfibrozil and Medrol (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.